As Congress debates orphan reforms, new analysis finds 65% of orphan drugs approved for a single rare disease
As Congress considers whether to shift away from orphan drug incentives that have provided a windfall for industry in some cases, a new FDA and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
